Nutriband has acquired 4P Therapeutics for $1.9 million. 4P Therapeutics will now become the pharmaceutical and development arm of Nutriband with a specific focus on transdermal and topical technologies, prescription drugs and clinical development. Steven Damon, chief executive officer of 4P Therapeutics, has been appointed to Nutriband’s board of directors. Included in the acquisition of 4P’s IP portfolio is Defent abuse deterrent patch technology, an opioid abuse deterrent platf...